Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
11 Apr 2018
Shield Therapeutics plc (LSE:STX) today announces its preliminary Group results for the year ended 31 December 2017. For full details view the press release here.